(-0.53%) 5 080.50 points
(-0.28%) 38 573 points
(-0.92%) 17 502 points
(0.24%) $83.01
(-1.39%) $1.630
(0.03%) $2 339.10
(0.33%) $27.44
(0.27%) $918.30
(-0.24%) $0.932
(-0.34%) $10.95
(-0.44%) $0.799
(-0.22%) $92.11
4 days till quarter result
(bmo 2024-04-29)
Expected move: +/- 10.91%
Live Chart Being Loaded With Signals
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally...
Stats | |
---|---|
Today's Volume | 7 147.00 |
Average Volume | 319 139 |
Market Cap | 220.00M |
EPS | £0 ( 2024-04-22 ) |
Next earnings date | ( £0 ) 2024-04-29 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.44 |
ATR14 | £0.927 (0.42%) |
Volume Correlation
Oxford BioMedica PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oxford BioMedica PLC Correlation - Currency/Commodity
Oxford BioMedica PLC Financials
Annual | 2022 |
Revenue: | £139.99M |
Gross Profit: | £69.18M (49.42 %) |
EPS: | £-0.480 |
Q2 | 2023 |
Revenue: | £43.06M |
Gross Profit: | £21.94M (50.95 %) |
EPS: | £-0.500 |
Q4 | 2022 |
Revenue: | £75.96M |
Gross Profit: | £33.05M (43.51 %) |
EPS: | £-0.140 |
Q2 | 2022 |
Revenue: | £64.03M |
Gross Profit: | £36.13M (56.43 %) |
EPS: | £-0.270 |
Financial Reports:
No articles found.
Oxford BioMedica PLC
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators